Neuropathy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: NRP001 MIFTS: 56	Neuropathy Categories: Immune diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Neuropathy

MalaCards integrated aliases for Neuropathy:

Name: Neuropathy ¹² ¹⁵ ³⁹ ¹⁷ ⁷¹

Peripheral Neuropathy ¹² ⁷¹

Peripheral Neuropathies ¹⁵

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Diseases of the nervous system

Polyneuropathies and other disorders of the peripheral nervous system

Other polyneuropathies

Polyneuropathy, unspecified

External Ids:

Disease Ontology ¹² DOID:870

NCIt ⁴⁹ C4731

SNOMED-CT ⁶⁷ 386033004

ICD10 ³² G62.9

EFO ¹⁷ EFO_0004149

UMLS ⁷¹ C0031117 C0442874

Sources

Summaries for Neuropathy

Disease Ontology : ¹² A nervous system disease that is located in nerves or nerve cells.

MalaCards based summary : Neuropathy, also known as peripheral neuropathy, is related to neuropathy, hereditary, with liability to pressure palsies and neuropathy, hereditary sensory and autonomic, type iia, and has symptoms including seizures, tremor and back pain. An important gene associated with Neuropathy is DLX6-AS1 (DLX6 Antisense RNA 1), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Aztreonam and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include nerves, breast and testes, and related phenotypes are behavior/neurological and cellular

Sources

Related Diseases for Neuropathy

Diseases in the Neuropathy family:

Autoimmune Neuropathy

Hereditary Neuropathies

Diseases related to Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2735)

#	Related Disease	Score	Top Affiliating Genes
1	neuropathy, hereditary, with liability to pressure palsies	35.2	SPTLC2 PMP22 MPZ MFN2 GJB1 GDAP1
2	neuropathy, hereditary sensory and autonomic, type iia	35.1	WNK1 SPTLC2 SPTLC1 SLC12A6 NGF KIF1A
3	neuropathy, hereditary sensory and autonomic, type v	35.1	WNK1 SPTLC1 NGF KIF1A
4	hypertrophic neuropathy of dejerine-sottas	35.0	PMP22 MPZ MFN2 GJB1 GDAP1
5	neuropathy, congenital hypomyelinating, 1, autosomal recessive	35.0	SPTLC2 SLC12A6 PMP22 MPZ MFN2 GJB1
6	neuropathy, hereditary sensory, type ie	35.0	SPTLC2 SPTLC1 DNMT1
7	hereditary sensory neuropathy	35.0	WNK1 SPTLC2 SPTLC1 NGF MPZ KIF1A
8	hereditary sensory and autonomic neuropathy type 1	35.0	SPTLC2 SPTLC1 DNMT1
9	hereditary motor and sensory neuropathy, type iic	34.9	MPZ MFN2 GJB1 GDAP1
10	neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux	34.9	SPTLC2 SPTLC1
11	diabetic neuropathy	34.9	PMP22 NGF MPZ
12	neuropathy, hereditary sensory and autonomic, type ia	34.9	WNK1 SPTLC2 SPTLC1
13	hereditary neuropathies	34.9	PMP22 MPZ MFN2 GJB1
14	deafness, x-linked 5, with peripheral neuropathy	34.8	DIAPH3 AIFM1
15	autonomic neuropathy	34.8	WNK1 SPTLC2 SPTLC1 SCN11A NGF KIF1A
16	sensory peripheral neuropathy	34.8	SPTLC1 SLC12A6 POLG PMP22 NGF MPZ
17	neuropathy, hereditary sensory and autonomic, type ic	34.8	SPTLC2 SPTLC1
18	agenesis of the corpus callosum with peripheral neuropathy	34.7	WNK1 SLC12A6
19	motor peripheral neuropathy	34.6	SLC12A6 POLG PMP22 MFN2 KIF1A GJB1
20	autoimmune peripheral neuropathy	34.5	MPZ GJB1
21	charcot-marie-tooth disease, x-linked dominant, 1	34.5	SPTLC1 PMP22 MPZ MFN2 GJB1 GDAP1
22	charcot-marie-tooth disease, axonal, type 2e	34.5	SPTLC1 SLC12A6 PMP22 NGF MPZ MFN2
23	neuropathy, hereditary sensory and autonomic, type iib	34.4	WNK1 KIF1A
24	charcot-marie-tooth disease, demyelinating, type 1b	34.4	PMP22 MPZ MFN2 GJB1 GDAP1
25	charcot-marie-tooth disease, demyelinating, type 1a	34.4	PMP22 MPZ MFN2 GJB1 GDAP1
26	charcot-marie-tooth disease, axonal, type 2b	34.4	SPTLC1 MPZ GJB1 GDAP1
27	charcot-marie-tooth disease, type 4d	34.4	MPZ GJB1 GDAP1
28	peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease	34.4	MPZ GJB1
29	charcot-marie-tooth disease, demyelinating, type 1c	34.3	PMP22 MPZ GJB1 GDAP1
30	axonal neuropathy	34.3	POLG PMP22 MFN2 GDAP1 GAN AIFM1
31	peripheral nervous system disease	34.3	SPTLC1 SLC12A6 SCN11A POLG PMP22 NGF
32	charcot-marie-tooth disease, axonal, type 2a1	34.3	MPZ MFN2 GDAP1
33	charcot-marie-tooth disease, demyelinating, type 1d	34.3	PMP22 MPZ GJB1 GDAP1
34	charcot-marie-tooth disease/hereditary motor and sensory neuropathy	34.3	SPTLC2 SPTLC1 SLC12A6 PMP22 MPZ MFN2
35	asymmetric motor neuropathy	34.3	PMP22 MFN2 GAN
36	charcot-marie-tooth disease and deafness	34.3	SPTLC2 SPTLC1 PMP22 MPZ MFN2 KIF1A
37	charcot-marie-tooth disease, type 4a	34.2	MPZ MFN2 GJB1 GDAP1
38	optic nerve disease	34.2	POLG NGF MT-ND4 MFN2 GDAP1
39	charcot-marie-tooth disease, demyelinating, type 1f	34.2	MPZ GJB1 GDAP1
40	charcot-marie-tooth disease, axonal, type 2t	34.2	SLC12A6 GDAP1 GAN
41	charcot-marie-tooth disease, dominant intermediate b	34.2	MPZ GJB1 GDAP1
42	charcot-marie-tooth disease, type 4c	34.2	MPZ GJB1 GDAP1
43	charcot-marie-tooth disease, axonal, type 2f	34.2	MPZ MFN2 GJB1 GDAP1
44	charcot-marie-tooth disease, type 4b2	34.2	MPZ GJB1 GDAP1
45	charcot-marie-tooth disease, dominant intermediate a	34.2	MPZ GJB1 GDAP1
46	charcot-marie-tooth disease, axonal, type 2d	34.2	MPZ MFN2 GJB1 GDAP1
47	charcot-marie-tooth disease, axonal, type 2b2	34.2	MPZ MFN2 GDAP1
48	charcot-marie-tooth disease, axonal, type 2i	34.1	MPZ GJB1 GDAP1
49	charcot-marie-tooth disease, axonal, type 2l	34.1	MPZ MFN2 GDAP1
50	charcot-marie-tooth disease, x-linked recessive, 2	34.1	MPZ MFN2 GJB1

Graphical network of the top 20 diseases related to Neuropathy:

Sources

Symptoms & Phenotypes for Neuropathy

UMLS symptoms related to Neuropathy:

seizures, tremor, back pain, headache, syncope, hemiparesis, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, neuralgia, neurologic symptoms, atypical facial pain

MGI Mouse Phenotypes related to Neuropathy:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.25	AIFM1 DNMT1 GAN GDAP1 GJB1 KIF1A
2	cellular	MP:0005384	10.22	AIFM1 DIAPH3 DNMT1 GAN GDAP1 GJB1
3	growth/size/body region	MP:0005378	10.21	AIFM1 DIAPH3 DNMT1 GAN GJB1 KIF1A
4	homeostasis/metabolism	MP:0005376	10.13	AIFM1 DIAPH3 GDAP1 GJB1 GP1BA MFN2
5	integument	MP:0010771	10	AIFM1 DIAPH3 DNMT1 GDAP1 KIF1A MPZ
6	mortality/aging	MP:0010768	10	AIFM1 DIAPH3 DNMT1 GAN GJB1 KIF1A
7	muscle	MP:0005369	9.56	AIFM1 GAN MFN2 NGF PMP22 POLG
8	nervous system	MP:0003631	9.5	AIFM1 DNMT1 GAN GDAP1 GJB1 KIF1A

Sources

Drugs & Therapeutics for Neuropathy

Drugs for Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 792)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Aztreonam

Approved

Phase 4

78110-38-0

5742832 5362041

Pravastatin

Approved

Phase 4

81093-37-0

54687

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Fexofenadine

Approved, Investigational

Phase 4

83799-24-0

3348

Allopurinol

Approved

Phase 4

315-30-0

2094

Dorzolamide

Approved

Phase 4

120279-96-1

5284549 3154

Dinoprostone

Approved

Phase 4

363-24-6

5280360

Granisetron

Approved, Investigational

Phase 4

109889-09-0

3510

Nabilone

Approved, Investigational

Phase 4

51022-71-0

5284592

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Naloxone

Approved, Vet_approved

Phase 4

465-65-6

5284596

Tramadol

Approved, Investigational

Phase 4

27203-92-5

33741

Mexiletine

Approved, Investigational

Phase 4

31828-71-4

4178

Zidovudine

Approved

Phase 4

30516-87-1

35370

Lopinavir

Approved

Phase 4

192725-17-0

92727

Ritonavir

Approved, Investigational

Phase 4

155213-67-5

392622

Telmisartan

Approved, Investigational

Phase 4

144701-48-4

65999

Darunavir

Approved

Phase 4

206361-99-1, 635728-49-3

213039

Rifampicin

Approved

Phase 4

13292-46-1

5381226 5458213

Liraglutide

Approved

Phase 4

204656-20-2

44147092

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

445643 439492 6473866

Levodopa

Approved

Phase 4

59-92-7

6047

Carbidopa

Approved

Phase 4

28860-95-9

34359

Glucagon

Approved

Phase 4

16941-32-5

Vildagliptin

Approved, Investigational

Phase 4

274901-16-5

6918537

Nortriptyline

Approved

Phase 4

72-69-5

4543

Hydromorphone

Approved, Illicit

Phase 4

466-99-9

5284570

Dexmedetomidine

Approved, Vet_approved

Phase 4

113775-47-6

5311068 68602

Diclofenac

Approved, Vet_approved

Phase 4

15307-86-5

3033

Testosterone

Approved, Experimental, Investigational

Phase 4

58-22-0, 481-30-1

10204 6013

Travoprost

Approved

Phase 4

157283-68-6

5282226

Bimatoprost

Approved, Investigational

Phase 4

155206-00-1

5311027

Glimepiride

Approved

Phase 4

93479-97-1

3476

Bromocriptine

Approved, Investigational

Phase 4

25614-03-3

31101

Propranolol

Approved, Investigational

Phase 4

525-66-6

4946

Cilostazol

Approved, Investigational

Phase 4

73963-72-1

2754

Fluticasone

Approved, Experimental

Phase 4

90566-53-3

62924

Methimazole

Approved

Phase 4

60-56-0

1349907

Metoprolol

Approved, Investigational

Phase 4

37350-58-6, 51384-51-1

4171

Bezafibrate

Approved, Investigational

Phase 4

41859-67-0

39042

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

Quinapril

Approved, Investigational

Phase 4

85441-61-8

54892

Acetaminophen

Approved

Phase 4

103-90-2

1983

Angiotensin II

Approved, Investigational

Phase 4

4474-91-3, 11128-99-7, 68521-88-0

172198

Candesartan cilexetil

Approved

Phase 4

145040-37-5

2540

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Interventional clinical trials:

(show top 50) (show all 2276)

#	Name	Status	NCT ID	Phase	Drugs
1	Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial	Unknown status	NCT00123136	Phase 4
2	Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study	Unknown status	NCT02372149	Phase 4	10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
3	Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY	Unknown status	NCT00235222	Phase 4	stavudine
4	An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis	Unknown status	NCT03380793	Phase 4	morinidazole
5	An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease	Unknown status	NCT03391440	Phase 4	morinidazole
6	The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair	Unknown status	NCT02419443	Phase 4	Gabapentin;Placebo
7	A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus	Unknown status	NCT01852318	Phase 4	pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
8	Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer	Unknown status	NCT01038154	Phase 4	Pravastatin
9	Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial	Unknown status	NCT00752440	Phase 4
10	Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN)	Unknown status	NCT01770964	Phase 4	Pregabalin;placebo
11	The Effects of Omega-3 Fatty Acids on Chemotherapy-induced Neuropathy and Inflammation in Patients With Breast Cancer	Unknown status	NCT01049295	Phase 4
12	Botox on Vulvar Vestibulitis	Unknown status	NCT00119886	Phase 4	Botulinum toxin
13	Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease	Unknown status	NCT02339142	Phase 4	intravenous corticosteroids (methylprednisolone)
14	Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery	Unknown status	NCT02535000	Phase 4	Duloxetine;Placebo
15	Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin	Unknown status	NCT03195153	Phase 4	Atorvastatin 80mg;ALLOPURINOL 300 MG;Atorvastatin 80mg AND allopurinol 300 mg
16	A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty	Unknown status	NCT02497911	Phase 4	Ropivicaine;Bupivicaine
17	Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.	Unknown status	NCT02033057	Phase 4
18	The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure	Unknown status	NCT01704339	Phase 4	QUTENZA
19	Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System	Unknown status	NCT00446810	Phase 4	Benfotiamine;Placebo
20	Effects of Pregabalin on Mechanical Hyperalgesia - EPOM	Unknown status	NCT00310583	Phase 4	Pregabalin
21	A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty	Unknown status	NCT02603900	Phase 4	ropivacaine;bupivacaine
22	The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain	Unknown status	NCT01417923	Phase 4	vitamin D
23	Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients	Unknown status	NCT02053298	Phase 4	Timolol & Dorzolamide
24	Absorption and Utilization of a Mixed Meal in Type 1 Diabetes: Creation of a Biological and In Silico Biobank for the Optimization of Artificial Pancreas Systems. A Pilot Study.	Unknown status	NCT01800734	Phase 4
25	Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients	Unknown status	NCT03091881	Phase 4	Granisetron 0.1 MG/ML;Placebos
26	Multicentre Randomised Controled Trial Comparing the Effect of a New Self-gripping Lightweight Polyester Mesh and a Normal Sutured Lightweight Polyester Mesh on the Incidence of Chronic Inguinodynia in Lichtenstein Hernioplasty.	Unknown status	NCT01830452	Phase 4
27	A Prospective Single Blind Randomised Controlled Study to Compare the Outcomes of Patients With Diabetes and Clinically Non-infected Neuro-ischaemic and Neuropathic Foot Ulcers Treated With and Without Oral Antibiotics.	Unknown status	NCT01418456	Phase 4	antibiotics
28	An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection	Completed	NCT01192113	Phase 4	Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
29	Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus	Completed	NCT03031834	Phase 4	Quinapril
30	A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).	Completed	NCT00156078	Phase 4	pregabalin
31	A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain	Completed	NCT00407511	Phase 4	Pregabalin
32	A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy	Completed	NCT00380913	Phase 4	Cesamet™ (nabilone)
33	An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy	Completed	NCT00159731	Phase 4	Pregabalin
34	A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy	Completed	NCT00159679	Phase 4	Pregabalin
35	A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)	Completed	NCT00726713	Phase 4
36	Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia	Completed	NCT00629681	Phase 4	Pregabalin
37	A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions	Completed	NCT03712475	Phase 4	Pregabalin
38	High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy	Completed	NCT04377399	Phase 4	Vitamin D
39	A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy	Completed	NCT00120341	Phase 4
40	A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study	Completed	NCT00614341	Phase 4
41	A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer	Completed	NCT00380965	Phase 4	Cesamet™ (nabilone)
42	The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients	Completed	NCT04238208	Phase 4	Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
43	Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial	Completed	NCT02923388	Phase 4	Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
44	A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment	Completed	NCT01675531	Phase 4	Targin
45	Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain	Completed	NCT01364298	Phase 4	Gabapentin/B-complex;Pregabalin
46	L-Arginine and Endothelial Dysfunction in Type 2 Diabetic Patients	Completed	NCT00902616	Phase 4
47	Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study	Completed	NCT01373983	Phase 4	Ziconotide
48	Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)	Completed	NCT02151149	Phase 4	nab-paclitaxel;Carboplatin
49	Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy	Completed	NCT01628627	Phase 4
50	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions	Completed	NCT00904202	Phase 4	Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch

Search NIH Clinical Center for Neuropathy

Sources

Genetic Tests for Neuropathy

Sources

Anatomical Context for Neuropathy

The Foundational Model of Anatomy Ontology organs/tissues related to Neuropathy:

¹⁹

Nerves

MalaCards organs/tissues related to Neuropathy:

⁴⁰

Breast, Testes, Skin, Lung, Heart, Brain, Spinal Cord

Sources

Publications for Neuropathy

Articles related to Neuropathy:

(show top 50) (show all 40000)

#	Title	Authors	PMID	Year
1	Histologic evaluation of femoral nerve demyelinating and axonal neuropathy in Wistar rats due to alendronate intake: a randomised study. ⁶¹	Theodora P...Antonia S	32099834	2020
2	The effect of rat nerve growth factor combined with vitamin B on peripheral neuropathy in multiple myeloma patients. ⁶¹	Yan M...Guo X	32567522	2020
3	Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy. ⁶¹	Micov AM...Stepanovic-Petrovic RM	32464241	2020
4	mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment. ⁶¹	Martin PY...Courteix C	32512114	2020
5	Insights into platinum-induced peripheral neuropathy-current perspective. ⁶¹	Lazic A...Stevanovic M	32209761	2020
6	Beneficial effects of ferulic acid alone and in combination with insulin in streptozotocin induced diabetic neuropathy in Sprague Dawley rats. ⁶¹	Dhaliwal J...Chopra K	32473246	2020
7	The isoform-specific functions of the c-Jun N-terminal kinase (JNK) in a mouse model of antiretroviral-induced painful peripheral neuropathy. ⁶¹	Sanna MD...Galeotti N	32416188	2020
8	Metformin protects from oxaliplatin induced peripheral neuropathy in rats. ⁶¹	Martinez NW...Court FA	32490289	2020
9	Escin alleviates peripheral neuropathy in streptozotocin induced diabetes in rats. ⁶¹	Suryavanshi SV...Kulkarni YA	32407839	2020
10	Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity. ⁶¹	Minami T...Ito A	32416186	2020
11	It is not your eyes. ⁶¹	Cohen DA...Gold DR	31009615	2020
12	A recessive Trim2 mutation causes an axonal neuropathy in mice. ⁶¹	Li JJ...Scherer SS	32205255	2020
13	Radiation optic neuropathy and stroke suspicion. ⁶¹	Ayoub E...Bertoletti L	32571566	2020
14	Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. ⁶¹	Sasaki K...Jabbour E	32170867	2020
15	A Randomized Controlled Trial to Assess the Effectiveness of Muscle Strengthening and Balancing Exercises on Chemotherapy-Induced Peripheral Neuropathic Pain and Quality of Life Among Cancer Patients. ⁶¹	Dhawan S...Shukla G	30888982	2020
16	Long lasting trigeminal neuropathy, limbic encephalitis and abdominal ganglionitis without primary cancer: An atypical case of Hu-antibody syndrome. ⁶¹	De Schamphelaere E...De Bleecker JL	32388246	2020
17	Treatment induced neuropathy of diabetes. ⁶¹	Gibbons CH	32247944	2020
18	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. ⁶¹	Dummer R...Duvic M	32502876	2020
19	Central nervous system complications associated with immune checkpoint inhibitors. ⁶¹	Vogrig A...Honnorat J	32312871	2020
20	Optic nerve atrophy and whole and regional brain atrophy in Leber's hereditary optic neuropathy with multiple sclerosis-like disease with m.11778G>A mutation. ⁶¹	Rosciszewska-Zukowska I...Bartosik-Psujek H	32387972	2020
21	Molecular analysis and clinical diversity of distal hereditary motor neuropathy. ⁶¹	Liu X...Fan D	32298515	2020
22	Linear mixed-effects models for the analysis of high-density electromyography with application to diabetic peripheral neuropathy. ⁶¹	Andreis FR...Marques JLB	32447652	2020
23	Protective effect of quercetin on streptozotocin-induced diabetic peripheral neuropathy rats through modulating gut microbiota and reactive oxygen species level. ⁶¹	Xie J...Shi X	32559841	2020
24	IFN-γ/mTORC1 decreased Rab11 in Schwann cells of diabetic peripheral neuropathy, inhibiting cell proliferation via GLUT1 downregulation. ⁶¹	Du W...Hao J	31970777	2020
25	Clinical characteristics of fibroblast growth factor receptor 3 antibody-related polyneuropathy: a retrospective study. ⁶¹	Kovvuru S...Roy B	32068339	2020
26	Agomelatine potentiates anti-nociceptive effects of morphine in a mice model for diabetic neuropathy: involvement of NMDA receptor subtype NR1 within the raphe nucleus and periaqueductal grey. ⁶¹	Ozcan S...Ozcan M	32336224	2020
27	The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. ⁶¹	Castellani F...Briani C	32284437	2020
28	ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy. ⁶¹	Caporali L...Taroni F	32219868	2020
29	Sarcoidosis with cutaneous perineural granulomas and neurological manifestations: A potential mimicker of leprosy. ⁶¹	Kazi R...Karunamurthy A	32022940	2020
30	Vestibular dysfunction in patients with auditory neuropathy detected by vestibular evoked myogenic potentials. ⁶¹	Hu J...Zhang Q	32089450	2020
31	Is ultrasound better than electrodiagnosis for the diagnosis of compressive neuropathy? ⁶¹	Simon NG...Preston DC	32362459	2020
32	Low brain-derived neurotrophic factor protein levels and single-nucleotide polymorphism Val66Met are associated with peripheral neuropathy in type II diabetic patients. ⁶¹	Azoulay D...Bashkin A	32124075	2020
33	The LFA-1 antagonist BIRT377 reverses neuropathic pain in prenatal alcohol-exposed female rats via actions on peripheral and central neuroimmune function in discrete pain-relevant tissue regions. ⁶¹	Noor S...Milligan ED	31918004	2020
34	Topical Delivery of Muscarinic Receptor Antagonists Prevents and Reverses Peripheral Neuropathy in Female Diabetic Mice. ⁶¹	Jolivalt CG...Calcutt NA	32327528	2020
35	Nutritional neuropathies. ⁶¹	Gwathmey KG...Grogan J	31837157	2020
36	Hypertrophic Interstitial Neuropathy of the Trigeminal Nerve: Case Report and Literature Review. ⁶¹	Wang AP...Reddy KKV	31620786	2020
37	Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. ⁶¹	Nyrop KA...Muss HB	32315091	2020
38	cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons. ⁶¹	Sasaki Y...DiAntonio A	32087251	2020
39	Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives. ⁶¹	da Costa R...Calixto JB	32352155	2020
40	Electrophysiology and ultrasonography in the diagnosis of ulnar neuropathy at the elbow. ⁶¹	Pelosi L...Mulroy E	32345517	2020
41	Reply to "Electrophysiology and ultrasonography in the diagnosis of ulnar neuropathy at the elbow". ⁶¹	Podnar S...Omejec G	32349940	2020
42	Treatment of diabetic peripheral neuropathy: a review. ⁶¹	Khdour MR	32067247	2020
43	Getting the balance right in auditory neuropathy. ⁶¹	Chen L	32327271	2020
44	Continuous subcutaneous insulin infusion and neuropathy in older people. ⁶¹	Rigalleau V...Mohammedi K	32276296	2020
45	Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy. ⁶¹	De Simoni D...Hoftberger R	32487720	2020
46	Recurrent alternating ophthalmoplegia with ipsilateral headache: unusual but possible manifestation of recurrent painful ophthalmoplegic neuropathy. ⁶¹	Kim JM...Lee SH	32504277	2020
47	The ataxic neuropathies. ⁶¹	Mathis S...Le Masson G	32556571	2020
48	Cerebellar ataxia, neuropathy, hearing loss, and intellectual disability due to AIFM1 mutation. ⁶¹	Pandolfo M...Vandernoot I	32337346	2020
49	Pupil fields in patients with Leber hereditary optic neuropathy. ⁶¹	Asakawa K...Shoji N	32518975	2020
50	Recurrent Bilateral Myelin Oligodendrocyte Glycoprotein Antibody Optic Neuritis in a Leber Hereditary Optic Neuropathy Carrier. ⁶¹	Raviskanthan S...Fok A	31842145	2020

Sources

Genes for Neuropathy

Genes related to Neuropathy (0 elite genes):

(show top 50) (show all 90)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	DLX6-AS1	DLX6 Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁸	16705037
2	GJB1	Gap Junction Protein Beta 1	Protein Coding	55.84	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
3	MPZ	Myelin Protein Zero	Protein Coding	55.08	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
4	GAN	Gigaxonin	Protein Coding	54.03	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
5	WNK1	WNK Lysine Deficient Protein Kinase 1	Protein Coding	53.51	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
6	PMP22	Peripheral Myelin Protein 22	Protein Coding	53.44	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
7	SLC12A6	Solute Carrier Family 12 Member 6	Protein Coding	52.91	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
8	SPTLC1	Serine Palmitoyltransferase Long Chain Base Subunit 1	Protein Coding	52.81	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
9	GDAP1	Ganglioside Induced Differentiation Associated Protein 1	Protein Coding	51.4	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
10	AIFM1	Apoptosis Inducing Factor Mitochondria Associated 1	Protein Coding	50.48	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
11	DIAPH3	Diaphanous Related Formin 3	Protein Coding	47.62	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
12	MFN2	Mitofusin 2	Protein Coding	45.43	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
13	KIF1A	Kinesin Family Member 1A	Protein Coding	44.58	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
14	GP1BA	Glycoprotein Ib Platelet Subunit Alpha	Protein Coding	44.31	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Proteins Variants (show sections)
15	SCN11A	Sodium Voltage-Gated Channel Alpha Subunit 11	Protein Coding	44.28	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
16	NGF	Nerve Growth Factor	Protein Coding	43.83	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
17	SPTLC2	Serine Palmitoyltransferase Long Chain Base Subunit 2	Protein Coding	43.37	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
18	POLG	DNA Polymerase Gamma, Catalytic Subunit	Protein Coding	42.9	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
19	DNMT1	DNA Methyltransferase 1	Protein Coding	42.66	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
20	MT-ND4	Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 4	Protein Coding	42.6	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Variants (show sections)
21	TDP1	Tyrosyl-DNA Phosphodiesterase 1	Protein Coding	42.56	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
22	RETREG1	Reticulophagy Regulator 1	Protein Coding	41.91	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
23	CCT5	Chaperonin Containing TCP1 Subunit 5	Protein Coding	41.54	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
24	ATL3	Atlastin GTPase 3	Protein Coding	41.37	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
25	PNPLA6	Patatin Like Phospholipase Domain Containing 6	Protein Coding	41.34	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Variants (show sections)
26	SLC25A46	Solute Carrier Family 25 Member 46	Protein Coding	41.3	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
27	PRX	Periaxin	Protein Coding	40.48	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
28	HINT1	Histidine Triad Nucleotide Binding Protein 1	Protein Coding	39.87	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
29	CTDP1	CTD Phosphatase Subunit 1	Protein Coding	38.71	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
30	SCN9A	Sodium Voltage-Gated Channel Alpha Subunit 9	Protein Coding	36.83	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
31	SETX	Senataxin	Protein Coding	34.64	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
32	DST	Dystonin	Protein Coding	33.77	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
33	TWNK	Twinkle MtDNA Helicase	Protein Coding	32.84	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
34	EGR2	Early Growth Response 2	Protein Coding	32.7	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
35	GARS1	Glycyl-TRNA Synthetase 1	Protein Coding	32.49	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Variants (show sections)
36	SOX10	SRY-Box Transcription Factor 10	Protein Coding	32.42	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
37	TRPV4	Transient Receptor Potential Cation Channel Subfamily V Member 4	Protein Coding	32.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries Variants (show sections)
38	MT-ND6	Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 6	Protein Coding	32.3	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
39	RAB7A	RAB7A, Member RAS Oncogene Family	Protein Coding	32.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Variants (show sections)
40	OTOF	Otoferlin	Protein Coding	31.75	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
41	DNM2	Dynamin 2	Protein Coding	31.71	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Proteins Variants (show sections)
42	TFG	Trafficking From ER To Golgi Regulator	Protein Coding	31.6	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
43	SBF2	SET Binding Factor 2	Protein Coding	31.5	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name Variants (show sections)
44	SH3TC2	SH3 Domain And Tetratricopeptide Repeats 2	Protein Coding	31.29	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
45	MT-ND1	Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 1	Protein Coding	31.2	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
46	MT-ATP6	Mitochondrially Encoded ATP Synthase Membrane Subunit 6	Protein Coding	31.15	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
47	ELP1	Elongator Complex Protein 1	Protein Coding	31.06	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Gene name Variants (show sections)
48	PRPS1	Phosphoribosyl Pyrophosphate Synthetase 1	Protein Coding	31.05	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
49	CNTNAP1	Contactin Associated Protein 1	Protein Coding	30.98	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
50	DYNC1H1	Dynein Cytoplasmic 1 Heavy Chain 1	Protein Coding	30.94	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)

Sources

Variations for Neuropathy

Copy number variations for Neuropathy from CNVD:

⁷

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	107544	17	15900000	22100000	Microdeletion		Neuropathy
2	107574	17	16000000	22200000	Copy number		Neuropathy
3	216423	6	92100000	98700000	Microdeletion	EPHA7	Neuropathy

Sources

Expression for Neuropathy

Search GEO for disease gene expression data for Neuropathy.

Sources

Pathways for Neuropathy

Pathways related to Neuropathy according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Neural Crest Differentiation ¹	10.81	PMP22 MPZ GJB1

Sources

GO Terms for Neuropathy

Cellular components related to Neuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016020	9.83	WNK1 SPTLC2 SPTLC1 SLC12A6 SCN11A POLG
2	serine C-palmitoyltransferase complex	GO:0017059	8.62	SPTLC2 SPTLC1

Biological processes related to Neuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mitochondrial fusion	GO:0008053	9.32	MFN2 GDAP1
2	sphingosine biosynthetic process	GO:0046512	9.26	SPTLC2 SPTLC1
3	sphingomyelin biosynthetic process	GO:0006686	9.16	SPTLC2 SPTLC1
4	positive regulation of lipophagy	GO:1904504	8.96	SPTLC2 SPTLC1
5	sphinganine biosynthetic process	GO:0046511	8.62	SPTLC2 SPTLC1

Molecular functions related to Neuropathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	serine C-palmitoyltransferase activity	GO:0004758	8.62	SPTLC2 SPTLC1

Sources

Sources for Neuropathy

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer</